INTRODUCTION {#s1}
============

Gastroesophageal adenocarcinoma (GEA) represents the third most common cause of cancer death worldwide.^[@B1]^ The majority of patients globally present with advanced-stage disease, in whom the median overall survival is approximately 11 months with combination chemotherapy.^[@B2]^ Later lines of systemic therapy such as ramucirumab,^[@B3],[@B4]^ immunotherapy,^[@B5],[@B6]^ and trifluridine/tipiracil^[@B7]^ improve survival by only 1 to 2 months compared with placebo. New effective therapeutics are needed.

Potential therapeutic targets include the fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) pathway, which stimulates angiogenesis, transformation, and proliferation of tumor cells.^[@B8]^ This pathway is mediated by a family of transmembrane tyrosine kinase receptors encoded by 4 genes (*FGFR1-FGFR4*).^[@B8]^ Oral tyrosine kinase inhibitors have demonstrated efficacy in bladder cancer and cholangiocarcinomas with genetic alternations, such as mutations or fusions of *FGFR1*, *FGFR2*, and *FGFR3* (although minimal activity with *FGFR* amplification), but toxicities such as hyperphosphatemia, stomatitis, and retinal toxicities have been reported in association with these agents.^[@B9]-[@B11]^ The FGFR2 receptor has a splice variant, FGFR2b (also known as FGFR2IIIb, KGFR, or K-sam),^[@B12]^ that is overexpressed in 2.5%-31.1% of GEAs depending on the antibody and assay used.^[@B13]-[@B16]^ Overexpression of FGFR2b has been demonstrated to be a result of either amplification or aberrant transcriptional upregulation of the *FGFR2* gene,^[@B8],[@B17]-[@B20]^ and in GEA, both FGFR2b overexpression and *FGFR2* gene amplification have been associated with a worse prognosis.^[@B21]-[@B23]^ Amplification of the *FGFR2* gene is associated with both the chromosomal instability and genomically stable subgroups of The Cancer Genome Atlas.^[@B15],[@B17]-[@B20],[@B24]^

Bemarituzumab (FPA144) is a first-in-class humanized immunoglobulin G1 monoclonal antibody specific to the splice-variant FGFR2b that inhibits binding of the ligands FGF7, FGF10, and FGF22.^[@B25]^ Specifically, bemarituzumab does not inhibit binding of FGF23, the ligand responsible for phosphate and vitamin D metabolism,^[@B26]^ thereby potentially avoiding the risk of hyperphosphatemia associated with pan-FGFR tyrosine kinase inhibitors.^[@B9]-[@B11]^ Bemarituzumab is also glycoengineered for increased affinity for the human Fc gamma RIIIA receptor expressed on natural killer cells, enabling enhanced antibody-dependent cell-mediated cytotoxicity.^[@B25]^ Bemarituzumab has demonstrated inhibition of FGFR2b phosphorylation and cell proliferation in FGFR2b-overexpressing gastric cancer xenograft models.^[@B25]^ Preclinical in vitro and in vivo studies identified that a bemarituzumab target trough serum concentration of ≥ 60 µg/mL achieves maximum efficacy (data on file; Five Prime Therapeutics, South San Francisco, CA).

In preclinical toxicity studies, bemarituzumab was tolerated in doses up to 100 mg/kg administered weekly for 13 weeks to cynomolgus monkeys. Dose-dependent microscopic corneal atrophy and mammary gland atrophy were observed in animals receiving treatment but not in the animals killed at the end of the 15-week recovery phase, suggesting the findings were reversible (data on file; Five Prime Therapeutics). This first-in-human, phase I, dose-escalation and expansion trial of bemarituzumab (FPA144-001 trial) was designed to evaluate the safety and recommended dose (RD) of bemarituzumab in patients with solid tumors and to evaluate the preliminary efficacy in patients with FGFR2b-overexpressing advanced-stage GEA or bladder cancer.

PATIENTS AND METHODS {#s2}
====================

Phase I Patient Population and Trial Design {#s3}
-------------------------------------------

FPA144-001 was an open-label, multicenter, nonrandomized trial (ClinicalTrials.gov identifier: [NCT02318329](https://clinicaltrials.gov/ct2/show/NCT02318329)).^[@B27],[@B28]^ Please see Protocol (online only). Informed consent was obtained for all patients, and the trial was conducted in compliance with local and national regulations and in accordance with the ethical principles based on the Declaration of Helsinki.

The trial was designed with 3 parts, 2 parallel dose escalations (parts 1a and 1b) and a part 2 expansion ([Fig 1](#f1){ref-type="fig"}). Patients in part 1a were required to have any locally advanced or metastatic solid tumor that had progressed after standard treatment or that was not appropriate for standard treatment. For parts 1b and 2, patients were required to have histologically documented recurrent or metastatic GEA or bladder cancer (part 2 only), measurable disease by RECIST version 1.1, and available tumor tissue for retrospective or prospective evaluation of FGFR2b expression and *FGFR2* amplification.

![Study design. IHC, immunohistochemistry; PK, pharmacokinetics; RD, recommended dose.](JCO.19.01834f1){#f1}

### Part 1a. {#s4}

The primary end point of part 1a was to determine the incidence of grade 3 or 4 adverse events (AEs) and clinical laboratory abnormalities defined as dose-limiting toxicities (DLTs). Part 1a followed a standard 3 + 3 dose-escalation design with 6 cohorts of patients receiving bemarituzumab at doses of 0.3, 1, 3, 6, 10, and 15 mg/kg administered intravenously every 2 weeks. Intrapatient dose escalation was not permitted. Dose-escalation decisions were agreed upon by the investigators and the study sponsor and based on an assessment of DLTs, AEs, and laboratory data during a 28-day DLT window.

### Part 1b. {#s5}

The primary end point of part 1b was to evaluate safety and pharmacokinetics (PK) in patients with GEA based on literature suggesting therapeutic antibodies may achieve lower serum concentrations in patients with GEA compared with other solid tumors.^[@B29]^

### Part 2. {#s6}

After identification of the RD from parts 1a and 1b, part 2 enrolled patients with GEA who were assigned to one of the following cohorts based on the level of FGFR2b expression in their tumor sample using a centrally performed validated laboratory-developed prototype immunohistochemistry (IHC) assay (LabCorp, Burlington, NC): cohort 1, high staining (≥ 10% of tumor cells with 3+ membranous staining); cohort 2, moderate staining (≥ 10% of tumor cells with 2+ staining and/or \< 10% of tumor cells with 3+ staining); cohort 3, low staining (1+ staining and/or \< 10% of tumor cells with 2+ staining); and cohort 4, negative staining. Initially, enrollment into the high FGFR2b group also required demonstration of *FGFR2* amplification (FGFR2-to-CEN10 ratio ≥ 2.0) by fluorescence in situ hybridization (FISH). After observing a 100% correlation in the first 12 patients between high overexpression by IHC and gene amplification by FISH, testing for amplification was conducted retrospectively. Cohort 5 enrolled patients with FGFR2b-overexpressing bladder cancer.

Treatment and Assessments {#s7}
-------------------------

Patients were administered bemarituzumab as a 30-minute intravenous infusion at a dose based on body weight every 2 weeks until disease progression, unacceptable toxicity, patient or physician decision, or death. Safety was monitored throughout the study and for 28 days after the last dose of treatment by history, physical examination, ECG, blood laboratory testing, and ophthalmologic exams. AEs were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03). A DLT was defined as any of the following events occurring in the first 28 days: absolute neutrophil count (ANC) of \< 0.5 × 10^9^/L for \> 5 days; febrile neutropenia (fever \> 38.3°C with ANC \< 1.0 × 10^9^/L); platelets \< 25 × 10^9^/L or \< 50 × 10^9^/L with bleeding requiring medical intervention; grade 3 thrombocytopenia for \> 7 days; grade 4 anemia; any grade ≥ 2 ophthalmologic AE that did not resolve within 7 days; AST or ALT \> 3× the upper limit of normal (ULN) and concurrent total bilirubin \> 2× ULN; or any nonhematologic AE of grade ≥ 3 (except controlled nausea, vomiting, and diarrhea).

Comprehensive ophthalmologic assessments (fundoscopy, slit lamp, ocular coherence tomography, and visual acuity) were conducted during the trial at screening, after 2 doses, at the time of any ophthalmologic symptoms, and at end of treatment. Any adverse ophthalmologic events were deemed events of special interest and followed until resolution. Additional slit lamp evaluations of the cornea were conducted every 6 weeks for the first 6 months (later amended to be conducted throughout therapy regardless of duration). Interim safety reviews were conducted by an independent data safety monitoring board (DSMB) during part 2 of this study in accordance with the DSMB Charter.

Multiple serum PK samples were collected during the first dose, followed by collection before and at the end of infusions, at subsequent dosing cycles, and approximately 28 days after the last dose. Tumor assessments were performed according to RECIST version 1.1 during screening and every 6 weeks from the first dose of bemarituzumab until week 24 and then every 12 weeks until study treatment discontinuation or withdrawal of consent. A complete response (CR) or partial response (PR) required confirmation within 4 to 6 weeks.

Statistical Methods {#s8}
-------------------

Up to 30 patients were planned for each cohort in part 2. Safety and PK analyses were conducted in all patients who received ≥ 1 dose of bemarituzumab. Patients were evaluable for efficacy if they had measurable disease at study entry and at least 1 postbaseline disease assessment. Descriptive summary statistics were provided for patient characteristics, safety, and PK variables.

Objective response rate (ORR) was calculated as the proportion of patients with best overall response as CR or PR per RECIST version 1.1. Disease control rate (DCR) was calculated as the proportion of patients with a best overall response of CR, PR, or stable disease. Duration of response (DOR) was calculated as the number of days from the first documentation of response to the first documentation of progressive disease or death, whichever occurred earlier.

RESULTS {#s9}
=======

Baseline Patient Characteristics {#s10}
--------------------------------

From November 24, 2014, to February 16, 2018, 79 patients at 17 sites across the United States, South Korea, and Taiwan were enrolled onto the study. Nineteen patients with solid tumors were enrolled in part 1a (including 3 patients with GEA, 6 with colorectal cancer, 2 with biliary cancer, and 1 each with neuroendocrine, submandibular, lung, peritoneal, esophageal, breast, bladder, and pancreatic cancer), 8 patients with GEA were enrolled in part 1b, and 52 patients with GEA (n = 45) or bladder cancer (n = 7) were enrolled in part 2 ([Fig 1](#f1){ref-type="fig"}). Baseline characteristics are listed in [Table 1](#T1){ref-type="table"}. The median number of bemarituzumab infusions across all patients was 4 (range, 1-97 infusions), and for patients with GEA, the median number of infusions was 5 (range, 1-34 infusions). As of the data cutoff date of February 20, 2019, 1 patient with bladder cancer remained on treatment. The majority of patients (72.2%) discontinued the study as a result of radiographic disease progression.

###### 

Patient Characteristics

![](JCO.19.01834t1)

Safety {#s11}
------

No DLTs were observed during the part 1a and 1b dose escalations, and no maximum-tolerated dose was identified. Seventy-four (93.7%) of 79 patients reported treatment-emergent AEs (TEAEs). TEAEs reported in ≥ 10% of patients by study part are listed in [Table 2](#T2){ref-type="table"}. The most frequently reported TEAEs were generally consistent with an advanced cancer population and included decreased appetite (30.4%), abdominal pain (29.1%), and fatigue (26.6%).

###### 

Adverse Events Occurring \> 10% of Patients in the Overall Patient Population

![](JCO.19.01834t2)

Treatment-related AEs (TRAEs) were reported in 40 (50.6%) of 79 patients. Fatigue (17.7%), nausea (11.4%), and dry eye (10.1%) were the most common TRAEs. Three patients reported infusion reactions (grades 1-3, in 1 patient each). Grade 3 or 4 TEAEs occurred in 40 patients (50.6%), and 6 of those patients (7.6%) had grade 3 or 4 TEAEs that were considered by the investigator to be treatment related. Eight grade 3 AEs were reported in the 6 patients (nausea \[2 patients\] and anemia, neutropenia, increased AST, increased alkaline phosphatase, vomiting, and an infusion reaction \[1 patient each\]).

Serious AEs (SAEs) occurred in 23 patients (29.1%), with 6 events in 5 patients (6.3%) assessed as treatment related. Nausea and vomiting were reported in 1 patient, and an infusion reaction was reported in 1 patient. Any ocular event that required intervention or drug discontinuation was deemed an event of special interest and categorized as an SAE. Three patients reported such ocular events (ulcerative keratitis, limbal stem-cell deficiency, and corneal dystrophy in 1 patient each). These 3 ocular events were all corneal and grade 2, were reported at doses ≥ 10 mg/kg, and were reported ≥ 70 days after the patient's first dose of bemarituzumab. The patient with ulcerative keratitis presented with ocular pain on study day 100 while receiving treatment at a dose of 15 mg/kg. Bemarituzumab was held for 1 dose, and the patient received a topical ophthalmologic antibiotic and then resumed bemarituzumab without recurrence of the AE. The patient with limbal stem-cell deficiency presented with decreased visual acuity on study day 448 while receiving treatment at a dose of 10 mg/kg. Ophthalmologic examination revealed conjunctivalization, bemarituzumab was permanently discontinued, the patient received an antibiotic ointment, and the AE resolved 60 days after the last dose of study drug. This AE was the only TRAE on the study resulting in treatment discontinuation. The patient with corneal dystrophy developed myopia on study day 104 (33 days after the sixth and final dose of bemarituzumab at 15 mg/kg), which resolved with corticosteroid eye drops. Of the 28 patients who received bemarituzumab at doses of ≥ 10 mg/kg for ≥ 70 days, ocular events of special interest were reported in 3 patients (10.7%). In addition, low-grade (grade 1 or 2) ocular TEAEs were reported in 23 (29.1%) of 79 patients, with the most common events being dry eye (17.7%) and increased lacrimation (6.3%). No retinal toxicity was reported.

Four patients died on study; 1 patient died as a result of septic shock, and 3 died as a result of progressive disease, with no deaths deemed by the investigator as related to bemarituzumab. No notable difference in the safety profile was identified based on tumor type (GEA *v* non-GEA) or level of FGFR2b expression.

PK {#s12}
--

Bemarituzumab serum concentration versus time profiles (group mean ± standard deviation) from cycle 1, dose 1 for 77 of 79 patients (excluding the 2 patients without full dose) are displayed in [Figure 2](#f2){ref-type="fig"}. Group mean estimated PK parameters using noncompartmental analysis from 75 of 79 patients (excluding the 4 patients without enough data or without full dose) are listed in [Table 3](#T3){ref-type="table"} by cohort. Bemarituzumab demonstrated nonlinear clearance from 0.3 mg/kg to 1 mg/kg and approximately linear clearance from 1 mg/kg to 15 mg/kg in patients, suggesting target-mediated clearance. Maximum concentration (C~max~) increased the dose proportionally, whereas exposure (area under the curve \[AUC\]) did not increase dose proportionally in the nonlinear dose range (0.3-1 mg/kg). In the linear dose range (1-15 mg/kg), both C~max~ and AUC increased dose proportionally. A slight accumulation of C~max~ and trough concentration (C~trough~) was observed with repeated every-2-week dosing.

![Mean (± standard deviation) bemarituzumab serum concentration versus time profiles after first dose (cycle 1, day 1). GEA, gastroesophageal adenocarcinoma; P1a, part 1a; P1b, part 1b; P2, part 2.](JCO.19.01834f2){#f2}

###### 

Bemarituzumab Pharmacokinetic Parameter Estimates Using Noncompartmental Analysis for Patients Enrolled in FPA144-001 After First Dose

![](JCO.19.01834t3)

A comparison of the PK parameters in the 3 patients with corneal toxicity versus those in the 25 patients who were dosed at ≥ 10 mg/kg for ≥ 70 days without corneal toxicity did not identify a clear association based on C~max~, C~trough~, or AUC; however, analyses are limited by the number of patients. The dose of 15 mg/kg every 2 weeks was identified as the RD, based on the observed clinical activity, the safety, and the ability of this dose to achieve the target trough of ≥ 60 µg/mL in most of the patient population. In patients with high FGFR2b-overexpressing GEA, responses were observed in the 1 patient dosed at 6 mg/kg, 1 of 4 patients dosed at 10 mg/kg, and 3 of 22 patients dosed at 15 mg/kg. All 5 patients with PRs achieved the predicted target C~trough~ at steady-state of ≥ 60 µg/mL.

Antitumor Activity {#s13}
------------------

Fifty-two (92.9%) of 56 patients with GEA enrolled across the study (parts 1a and 1b combined) were efficacy evaluable per protocol, and all received a dose of at least 6 mg/kg every 2 weeks. Twenty-eight of these patients had tumors that had high FGFR2b overexpression (all *FGFR2* amplified by FISH), 4 patients had tumors with moderate expression, 12 patients had tumors with low expression, and 8 patients had tumors with no or unknown expression. All tumors with moderate, low, or no or unknown FGFR2b expression were nonamplified by FISH ([Table 1](#T1){ref-type="table"}). The ORR was 17.9% (95% CI, 6.1% to 36.9%) in patients with GEA with high FGFR2b overexpression, with a median DOR of 12.6 weeks (range, 9.1-19.1 weeks; [Fig 3](#f3){ref-type="fig"}). Stable disease was the best observed response in 13 additional patients, leading to an overall DCR (PR plus stable disease) of 64.3% (95% CI, 44.1% to 81.4%) in the subgroup with high FGFR2b overexpression ([Fig 4](#f4){ref-type="fig"}).

![Objective response and duration of follow-up in FGFR2b-positive gastric cancer.](JCO.19.01834f3){#f3}

![Waterfall plot of best percent change in sum of diameters from baseline in FGFR2b-positive gastric cancer. FPA144, bemarituzumab.](JCO.19.01834f4){#f4}

In the 12 patients with GEA with low FGFR2b overexpression, there was 1 confirmed response (ORR, 8.3%; 95% CI, 0.2% to 38.5%), with a DOR of 18.1 weeks. The blood from this patient with tumor response tested negative for *FGFR2* circulating tumor DNA amplification. There were no responses in the subgroups with moderate (n = 4) and no or unknown (n = 10) FGFR2b overexpression.

Six patients with bladder cancer selected for FGFR2b overexpression (high, n = 5; and low, n = 1) were evaluable for efficacy. No responses were observed. Four patients experienced a best response of stable disease for a median of 11.3 weeks (range, 10.1-17.6 weeks). Of note, 1 additional patient with FGFR2b-overexpressing bladder cancer was enrolled in part 1a at a dose of 3 mg/kg every 2 weeks. The patient had a history of surgically resected bladder cancer with recurrent disease that was diagnosed by positron emission tomography (PET) scan and, on study, experienced a complete metabolic response by PET scan, which was ongoing at the time of data cutoff (49 months).

DISCUSSION {#s14}
==========

This first-in-human study demonstrated that bemarituzumab, an afucosylated monoclonal antibody directed against FGFR2b, can be safely administered in patients with advanced cancer at doses up to 15 mg/kg every 2 weeks. Evidence of monotherapy activity was observed in heavily pretreated patients with high FGFR2b-overexpressing GEA. The RD was determined to be 15 mg/kg every 2 weeks based on safety and clinical responses observed at dose levels that achieved the target trough concentration of bemarituzumab. Consistent with selective targeting of FGFR2b by bemarituzumab, AEs associated with the pan-FGFR oral tyrosine kinase inhibitors, such as stomatitis and hyperphosphatemia, were not observed with bemarituzumab. However, reversible TRAEs of grade 2 symptomatic corneal events, which required intervention and in one case drug discontinuation, were reported in 3 (10.7%) of 28 patients who were treated with a dose of ≥ 10 mg/kg for ≥ 70 days. An analysis of PK parameters did not identify a clear association between C~max~, C~trough~, or AUC for corneal events; however, the small number of patients limits definitive conclusions.

The mechanism of the corneal toxicity is hypothesized to be a result of inhibition of FGF10, 1 of the 3 growth factors inhibited by bemarituzumab, and involved in the regulation of corneal epithelial wound healing.^[@B30],[@B31]^ No predisposing clinical factors were identified by medical history review or baseline ophthalmologic examinations in patients who developed corneal events compared with those who did not. In addition, no precursor findings were identified during the every-6-week ophthalmologic evaluations in the patients who developed corneal toxicity compared with those who did not. These analyses are limited because of the small number and poor prognosis of patients enrolled in a phase I trial, which lead to a low number of patients exposed to prolonged dosing (\> 70 days) of bemarituzumab.

Monotherapy efficacy has been disappointing with noncytotoxic agents in GEA.^[@B3],[@B5],[@B32]-[@B35]^ The ORR observed in this study in advanced-stage patients with high FGFR2b-overexpressing GEA was 17.9% (95% CI, 6.1% to 36.9%), and the DCR was 64.3% (95% CI, 44.1% to 81.4%). This ORR compares favorably with that of other noncytotoxic agents in GEA, such as ramucirumab (ORR, 3.2%)^[@B3]^ and checkpoint inhibitors (ORR, 12%-16%)^[@B5],[@B6]^ in the late-line GEA setting, warranting further evaluation.

Because of the poor prognosis of GEA with first-line therapy, the majority of patients do not receive third-line and later therapies.^[@B4],[@B36]-[@B38]^ The monotherapy activity of bemarituzumab and its lack of significant overlapping toxicities with standard platinum and fluoropyrimidine chemotherapeutic agents suggest that combining bemarituzumab with chemotherapy may potentially benefit more patients in the front-line setting of FGFR2b-overexpressing GEA. Early safety data suggest that bemarituzumab combined with oxaliplatin, fluorouracil, and leucovorin (mFOLFOX6) is tolerable in patients with advanced-stage GI cancers,^[@B39]^ and a randomized, placebo-controlled, phase III study of mFOLFOX6 with bemarituzumab in patients with newly diagnosed advanced-stage GEA, the FIGHT trial (ClinicalTrials.gov identifier: [NCT03694522](https://clinicaltrials.gov/ct2/show/NCT03694522)), initiated enrollment in September 2018.^[@B40]^

Presented in part at the 52nd Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 3-7, 2016, and in part at the 53rd Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 2-6, 2017.
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